Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 3;11(1):11681.
doi: 10.1038/s41598-021-91099-1.

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes

Affiliations

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes

Juliana Piedade et al. Sci Rep. .

Abstract

The role of liver stiffness measurement (LSM) after sustained virological response (SVR) in HCV patients treated by direct-acting antivirals (DAAs) remains unclear. We aimed to evaluate LSM regression value after SVR and to identify risk factors associated with liver related complications (LRC) or death. This retrospective study analyzed patients with LSM ≥ 10 kPa with LSM by transient elastography pre-DAAs and post-SVR. Patients with previous hepatic decompensation were excluded. Medical records were reviewed to identify primary outcomes. Kaplan-Meier curves and time-to-event Cox proportional-hazard models were performed. 456 patients [65% female, 62 years (IQR 57-68)] were included. During a follow-up of 2.3 years (IQR 1.6-2.7), 28 patients developed 37 outcomes [rate = 29.0 (95% CI 20.0-42.0) per 1000 person-years]. The cumulative incidence of outcomes was significantly lower in patients who regressed LSM ≥ 20% [3.4% (95% CI 1.8-7.0) vs. 9.0% (5.5-14.5), p = 0.028]. In a multivariate Cox-model [HR(95% CI)], male gender [HR = 3.00 (1.30-6.95), p = 0.010], baseline albumin < 3.5 mg/dL [HR = 4.49 (1.95-10.34), p < 0.001] and baseline unfavorable Baveno-VI [HR = 4.72 (1.32-16.83), p = 0.017] were independently associated and LSM regression ≥ 20% after SVR had a trend to reduce the risk of LRC or death [HR = 0.45 (0.21-1.02), p = 0.058]. The use of simple parameters before DAAs and repetition of LSM post-SVR can identify patients with different risks for severe outcome after HCV eradication.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study flowchart for inclusion of patients.
Figure 2
Figure 2
Cumulative incidence of liver related complications or death according to characteristics before HCV treatment (A) albumin levels (< 3.5 mg/dL vs. ≥ 3.5 mg/dL) and (B) Baveno VI status (unfavorable vs favorable) [all log-rank tests]; SVR sustained virological response.
Figure 3
Figure 3
Cumulative incidence of liver related complications or death according to regression of liver stiffness measurement (LSM) after sustained virological response (SVR) [all log-rank tests].

Similar articles

Cited by

References

    1. Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst. Rev. 2017;6:12143. doi: 10.1002/14651858.CD012143.pub2. - DOI - PMC - PubMed
    1. Pecoraro V, Banzi R, Cariani E, et al. New direct-acting antivirals for the treatment of patients with hepatitis C virus infection: A systematic review of randomized controlled trials. J. Clin. Exp. Hepatol. 2019;9(4):522–538. doi: 10.1016/j.jceh.2018.07.004. - DOI - PMC - PubMed
    1. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis c virus infection: A systematic review. Ann. Intern. Med. 2017;166(9):637–648. doi: 10.7326/M16-2575. - DOI - PMC - PubMed
    1. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol.69(2), 461–511 10.1016/j.jhep.2018.03.026 (2018). - PubMed
    1. Ghany MG, Morgan TR, Panel A-IHCG Hepatitis C guidance 2019 update: American Association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. doi: 10.1002/hep.31060. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances